

Cannabidiol for the treatment of patients at a high-risk of psychosis

Submission date 01/08/2018	Recruitment status No longer recruiting	☒ Prospectively registered
		☐ Protocol
Registration date 31/08/2018	Overall study status Completed	☐ Statistical analysis plan
		☐ Results
Last Edited 21/02/2022	Condition category Mental and Behavioural Disorders	☐ Individual participant data
		☐ Record updated in last year

Plain English summary of protocol

Background and study aims

Psychotic disorders such as schizophrenia typically affect young people and rank as one of the most disabling conditions worldwide. They pose an enormous burden on those affected and their families. They also cost society a great deal. In England alone, the total cost to society for services caring for people with schizophrenia and from lost employment is estimated to be £11.8 billion per year. Estimates suggest that in England alone, around 15,763 people every year have early symptoms of psychosis. Around a third of such people who are clinically at high risk (CHR) of developing psychosis will do so over the next 3 years. CHR patients commonly experience low level anxiety and psychotic symptoms such as delusions (e.g. false beliefs) and hallucinations (e.g. hearing voices that are not there). Typically these experiences are short-lasting or less severe compared to when they develop frank psychosis. We would like to prevent young people from developing psychotic illnesses. However, this is not easy, as it is not possible to accurately predict which CHR person will later develop psychosis. Also, current treatments do not always work. The medications (such as antipsychotic drugs) that we have available were originally developed for those with frank psychosis, and only have a modest benefit and are not tolerated very well. As treatments have to be offered to all CHR patients and not just those who will later develop frank psychosis, this also raises ethical concerns. Hence, at the moment, most CHR patients typically receive practical help and support (e.g. for housing or vocational support) and help from clinicians to address current issues.

Cannabidiol (CBD), a naturally available chemical found in the extract of cannabis plant, has emerged as a promising candidate as it displays anti-anxiety and anti-psychotic like properties in animals and humans. It has also been tolerated very well in human studies. We have recently tested this in a small number of CHR patients by giving them a 600 mg capsule of CBD daily for a short period (3 weeks) and comparing it with a group of CHR patients who were given an inactive drug. Results from these small studies suggest that CBD may be useful in treating symptoms in CHR patients. CBD was also safe and tolerated well by CHR patients. However, we do not know whether CBD treatment will actually be useful in providing symptom relief in CHR patients. A large clinical trial comparing CBD to placebo is needed to test this. Therefore, we aim to test whether CBD treatment will actually be useful in providing symptom relief in CHR patients in a large clinical trial.

Who can participate?

People aged 18-35 who have a diagnosis of a clinical high-risk state for psychosis with 'attenuated psychotic symptoms'

What does the study involve?

Patients will be randomly allocated to receive one of two treatments. Half of them will receive the same dose of CBD (600 mg once a day) given in capsule form and the other half will receive placebo capsule. In this study, patients will receive the treatment for 6 months. Neither the researchers nor patients will know what they have been treated with during the study. At the end of treatment, we will compare whether those who received CBD were significantly better off in terms of the symptoms that they were experiencing before they started treatment compared to those who received placebo. We will also study a subgroup of people (50 of those receiving CBD and 50 of those receiving placebo) to study brain chemistry and function using brain scanning (MRI scanners) to understand how CBD may work.

What are the possible benefits and risks of participating?

Patients taking part in the study may or may not receive any benefits from taking CBD as part of the study. CBD treatment might improve some of the psychological problems that patients may be experiencing. However, this is by no means certain, which is why we are conducting this study. Previous research has shown that the effects of CBD are very subtle. Apart from some mild sleepiness, mild diarrhea and nausea no adverse effects have been reported. Nevertheless, any unpleasant effects associated with taking part in the trial will be recorded throughout the study. The MRI scan procedure that will be employed is painless and safe and there are no known health risks. The MRI scanner makes loud noises while it is operating and participants will provide participants with headphones or earplugs to reduce the noise to safe levels. Some people find that being in an MRI scanner makes them feel anxious and/or claustrophobic, even if they have not experienced claustrophobia before. A member of staff will be in constant contact with participants via an intercom, and if they feel uncomfortable in any way the scanning can be stopped.

Further, the information we obtain from this study may help us to treat patients with mental health problems more effectively in the future.

Where is the study run from?

Institute of Psychiatry, Psychology & Neuroscience of Kings College London (UK)

When is the study starting and how long is it expected to run for?

July 2017 to May 2023

Who is funding the study?

National Institute for Health Research Efficacy and Mechanism Evaluation Programme (EME) (UK)

Who is the main contact?

Dr Sagnik Bhattacharyya
sagnik.2.bhattacharyya@kcl.ac.uk

Contact information

Type(s)

Public

Contact name

Dr Sagnik Bhattacharyya

Contact details

Department of Psychosis Studies
Institute of Psychiatry, Psychology & Neuroscience, KCL
16 De Crespigny Park
London
United Kingdom
SE5 8AF
+44 (0)2078480002
sagnik.2.bhattacharyya@kcl.ac.uk

Additional identifiers

Protocol serial number

CANTOP-RCT

Study information

Scientific Title

CANnabidiol as a Treatment fOr clinical high-risk state Psychosis - a Randomised Clinical Trial (CANTOP-RCT)

Acronym

CANTOP-RCT

Study objectives

Efficacy/tolerability hypotheses:

1. CBD treatment will reduce the severity of attenuated psychotic symptoms in CHR patients as measured using established criteria compared to placebo
2. Greater proportion of patients treated with CBD will not meet the criteria for 'attenuated psychosis syndrome' compared to placebo
3. CBD will reduce distress associated with attenuated psychotic symptoms in CHR patients as measured using established criteria compared to placebo
4. CBD will reduce the severity of anxiety symptoms in CHR patients as measured using established rating scales compared to placebo
5. CBD will improve social and role functioning in CHR patients as measured using established rating scales compared to placebo
6. CBD will not be associated with greater incidence of side-effects compared to placebo

Mechanistic hypotheses:

7. CBD will modulate brain activation in the medial temporal cortex and basal ganglia as measured using fMRI while performing verbal paired memory and emotional (fear) processing tasks in CHR patients compared to placebo
8. CBD will modulate brain activation in the medial temporal cortex and basal ganglia as measured using arterial spin labeling in CHR patients compared to placebo
9. Cannabidiol will attenuate glutamate levels in the hippocampus as measured using proton magnetic resonance spectroscopy in CHR patients compared to placebo

Ethics approval required

Old ethics approval format

Ethics approval(s)

Ethics approval pending with intention to submit by November 2018

Primary study design

Interventional

Study design

Interventional pragmatic randomised placebo-controlled trial

Study type(s)

Treatment

Health condition(s) or problem(s) studied

Clinical high-risk for psychosis (CHR)

Interventions

Participants will be randomised into either the intervention or control group using block randomisation. Randomisation will be double-blind and stratified by site.

Participants both groups will receive treatment as usual (TAU), which is the standard clinical care provided to CHR psychosis patients in NHS early intervention services.

The intervention group will receive TAU and a single daily dose of cannabidiol (CBD) in capsule form for 6 months.

The control group will receive TAU and a placebo capsule to take daily for 6 months.

Both CBD and the placebo will be given as matched capsules.

Patients will be followed up for a period of 6 months.

Intervention Type

Drug

Phase

Phase II

Drug/device/biological/vaccine name(s)

Cannabidiol (CBD)

Primary outcome(s)

Change in the severity of psychotic symptoms, assessed using the Comprehensive Assessment of At-Risk Mental States (CAARMS) questionnaire at the baseline and at the end of the study (day 182)

Key secondary outcome(s)

The following will be assessed at the baseline and at the end of the study (day 182):

1. Changes in the distress associated with psychotic symptoms, assessed using the Comprehensive Assessment of At-Risk Mental States (CAARMS) questionnaire
2. Changes in the severity of anxiety symptoms assessed using the Hospital Anxiety and Depression Scale (HADS) and in the level of global functioning (assessed using the social and role functioning scale)
3. Clinical remission, as defined as no longer meeting the criteria for a diagnosis of clinical high-risk: attenuated psychosis syndrome using the CAARMS questionnaire

Completion date

31/05/2023

Eligibility

Key inclusion criteria

1. Aged 18-35
2. Diagnosed with a clinical high-risk state for psychosis (CHR)
3. 'Attenuated psychotic symptoms' sub-group (CHR-APS) as defined using the CAARMS (Comprehensive Assessment of At-Risk Mental States) criteria

Participant type(s)

Patient

Healthy volunteers allowed

No

Age group

Adult

Lower age limit

18 Years

Upper age limit

35 Years

Sex

All

Key exclusion criteria

1. History of a previous psychotic or manic episode lasting 7 days or more
2. Neurological disorders (e.g. epilepsy) or severe intercurrent illness
3. Current treatment with psychotropic medication or previous treatment with antipsychotic medication for more than 7 days
4. IQ of less than 70
5. Females who are pregnant, lactating or not using contraception

Date of first enrolment

01/09/2022

Date of final enrolment

30/09/2022

Locations

Countries of recruitment

United Kingdom

England

Study participating centre
Institute of Psychiatry, Psychology & Neuroscience (IoPPN), KCL
London
United Kingdom
SE5 8AF

Study participating centre
University of Manchester
Manchester
United Kingdom
M13 9PL

Study participating centre
University of Birmingham
United Kingdom
B4 7BD

Study participating centre
University of Newcastle
United Kingdom
NE1 7RU

Study participating centre
Cambridgeshire & Peterborough NHS Foundation trust/ University of Cambridge
United Kingdom
CB4 1PR

Sponsor information

Organisation
King's College London and South London and Maudsley NHS Foundation Trust

ROR
<https://ror.org/015803449>

Funder(s)

Funder type

Not defined

Funder Name

Efficacy and Mechanism Evaluation Programme

Alternative Name(s)

NIHR Efficacy and Mechanism Evaluation Programme, Efficacy and Mechanism Evaluation (EME), EME

Funding Body Type

Government organisation

Funding Body Subtype

National government

Location

United Kingdom

Results and Publications

Individual participant data (IPD) sharing plan

The data sharing plans for the current study are unknown and will be made available at a later date

IPD sharing plan summary